Search results for "immunotherapy"

showing 10 items of 830 documents

Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation …

2016

Abstract Introduction: IELSG32 is an international randomized phase II trial with 2 key clinical questions in pts with PCNSL. The first question focused on optimal induction therapy, and results of the 1st randomization have demonstrated that MATRix combination (methotrexate (MTX), cytarabine (ARAC), thiotepa, rituximab (R)) is associated with significantly better outcome [Ferreri AJ, et al. Lancet Haematol 2016]. The second question addresses the efficacy and neurotolerability of ASCT, as an alternative to WBRT as consolidation. Herein, we report the results of the 2nd randomization (NCT01011920). Methods: HIV-neg pts 18-70 ys and ECOG PS ≤3 with new histology-proven PCNSL and measurable d…

medicine.medical_specialtyIntention-to-treat analysisRandomizationbusiness.industryImmunologyCell BiologyHematologyThioTEPANeutropeniamedicine.diseaseBiochemistry3. Good health03 medical and health sciences0302 clinical medicineQuality of lifeChemoimmunotherapy030220 oncology & carcinogenesisInternal medicineImmunologymedicineClinical endpointRituximabbusiness030215 immunologymedicine.drugBlood
researchProduct

Harnessing HLA‐E‐restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID‐19

2020

SARS-CoV-2 is spreading worldwide, and is a pandemic virus that has infected almost 5 million individuals and causing 300.000 deaths, as of mid-May 2020. Because SARS-CoV-2 is a new virus in humans there are currently no vaccines, monoclonal antibodies (mAbs) or even effective drugs available. Human convalescent plasma transfusion is an option for either prophylactic or therapeutic treatment of COVID-19 patients, but its administration to patients who are affected by severe pulmonary disease is associated with increased risk of transfusion-related acute lung injury (TRALI).

medicine.medical_specialtyLymphocyte TransfusionHematologymedicine.drug_classbusiness.industryvirusesmedicine.medical_treatmentHematologyImmunotherapyLung injuryMonoclonal antibodyVirus03 medical and health sciences0302 clinical medicineHLA-E030220 oncology & carcinogenesisInternal medicineImmunologymedicinebusinessCD8030215 immunologyBritish Journal of Haematology
researchProduct

Efficacy of Grass Pollen Allergen Sublingual Immunotherapy Tablets for Seasonal Allergic Rhinoconjunctivitis: A Systematic Review and Meta-analysis.

2015

IMPORTANCE: Randomized clinical trials (RCTs) and meta-analyses of sublingual immunotherapy (SLIT) for the treatment of seasonal allergic rhinoconjunctivitis (SARC) have shown a modest clinical benefit compared with placebo. Furthermore, indirect comparison by meta-analyses showed that subcutaneous immunotherapy is more effective than SLIT. Despite these data, SLIT has become the most prescribed treatment of SARC in Europe in recent years, and it was approved by the US Food and Drug Administration for the treatment of SARC to grass pollen in the United States on April 1, 2014. OBJECTIVE: To assess the efficacy and safety of the grass pollen sublingual tablets licensed as drugs in the treatm…

medicine.medical_specialtyMEDLINECochrane LibraryPlaceboPlant Extractlaw.inventionRandomized controlled triallawInternal medicineInternal MedicinemedicineClinical endpointmedia_common.cataloged_instanceHumansEuropean unionAdverse effectmedia_commonConjunctivitis AllergicSublingual Immunotherapybusiness.industryPlant ExtractsAllergenMedicine (all)Rhinitis Allergic SeasonalAllergensAntigens PlantMeta-analysisImmunologybusinessHumanJAMA internal medicine
researchProduct

Combined 5-fluorouracil and recombinant alpha-2a-interferon vs. 5-fluorouracil alone in metastatic colorectal carcinoma: a multicenter randomized stu…

1991

medicine.medical_specialtyPathologyColorectal cancermedicine.medical_treatmentInterferon alpha-2GastroenterologyDrug Administration ScheduleMetastasisInterferonInternal medicinemedicineCarcinomaHumansChemotherapyEpitheliomabusiness.industryInterferon-alphaGeneral MedicineImmunotherapymedicine.diseaseCombined Modality TherapyRecombinant ProteinsOncologyFluorouracilColonic NeoplasmsSurgeryFluorouracilbusinessmedicine.drugJournal of surgical oncology. Supplement
researchProduct

Adherence issues related to sublingual immunotherapy as perceived by allergists.

2010

Silvia Scurati1, Franco Frati1, Gianni Passalacqua2, Paola Puccinelli1, Cecile Hilaire1, Cristoforo Incorvaia3, Italian Study Group on SLIT Compliance 1Scientific and Medical Department, Stallergenes, Milan, Italy; 2Allergy and Respiratory Diseases, Department of Internal Medicine, Genoa; 3Allergy/Pulmonary Rehabilitation, ICP Hospital, Milan, ItalyObjectives: Sublingual immunotherapy (SLIT) is a viable alternative to subcutaneous immunotherapy to treat allergic rhinitis and asthma, and is widely used in clinical practice in many European countries. The clinical efficacy of SLIT has been established in a number of clinical trials and meta-analyses. However, because SLIT is self-administered…

medicine.medical_specialtyPathologygenetic structuresefficacyAlternative medicineMedicine (miscellaneous)Adherence Cost Efficacy Side effects Sublingual immunotherapySettore MED/10 - Malattie Dell'Apparato Respiratoriosublingual immunotherapyALLERGENcostmedicineSubcutaneous immunotherapySublingual immunotherapyadherenceClinical efficacyIntensive care medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)sublingual immunoterapyOriginal ResearchAsthmaAEROALLERGENSadherence; sublingual immunotherapy; efficacy; cost; side effectsbusiness.industryHealth Policymedicine.diseaseSliteye diseasesClinical trialside effectsPatient Preference and Adherenceadherence; sublingual immunoterapy; efficacy; cost; side effects.immunotherapysense organsAllergistsADHERENCE TO TREATMENTbusinessSocial Sciences (miscellaneous)
researchProduct

S2k guidelines for Merkel cell carcinoma (MCC, neuroendocrine carcinoma of the skin) – update 2018

2019

Merkel cell carcinoma (MCC, ICD-O M8247 / 3) is a rare malignant primary skin tumor with epithelial and neuroendocrine differentiation. The neoplastic cells share many morphological, immunohistochemical and ultrastructural characteristics with Merkel cells of the skin. The diagnosis of MCC is rarely made on clinical grounds. Histological and immunohistochemical studies are usually required to confirm the clinical suspicion. Given the frequent occurrence of occult lymph node metastasis, sentinel lymph node biopsy should be performed once distant metastasis has been ruled out by cross-sectional imaging. Primary tumors without evidence of organ metastases are treated with complete surgical exc…

medicine.medical_specialtySkin Neoplasmsmedicine.medical_treatmentSentinel lymph nodeMedizinAntineoplastic AgentsDermatologyNeuroendocrine differentiation030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineBiopsyCarcinomaHumansMedicineNeoadjuvant therapyAgedNeoplasm Stagingmedicine.diagnostic_testbusiness.industryMerkel cell carcinomaPrognosismedicine.diseaseNeoadjuvant TherapyCarcinoma Merkel CellRadiation therapymedicine.anatomical_structureLymphatic MetastasisImmunotherapyRadiologyNeoplasm Recurrence LocalCognition DisordersbusinessMerkel cell
researchProduct

Oral complaints in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation

2021

Background Acute myeloid leukemia belongs to proliferative diseases of the hematopoietic system. It is currently the leading indication for allogeneic hematopoietic stem cell transplantation. This study was designed to determine the most common subjective oral mucosa complaints in patients with acute myeloid leukemia after allogeneic hematopoietic cell transplantation, in relation to the type of conditioning used. Material and Methods Eighty patients diagnosed with acute myeloid leukemia were assigned to two groups depending on the intensity of the conditioning regimen before transplantation: myeloablative and reduced-intensity chemotherapy. The oral symptoms were evaluated based on an auth…

medicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationInternal medicineMedicineHumanstumor microenvironmentdendritic cellsOral mucosaGeneral DentistryUNESCO:CIENCIAS MÉDICASRetrospective StudiesChemotherapyOral Medicine and Pathologybusiness.industryResearchHematopoietic Stem Cell TransplantationMyeloid leukemiaoral cancerDysgeusiaTransplantationclec9aHaematopoiesisLeukemia Myeloid Acutemedicine.anatomical_structureOtorhinolaryngologyTaste disorderQuality of LifeSurgeryimmunotherapymedicine.symptombusiness
researchProduct

Update on the principles and novel local and systemic therapies for the treatment of non-infectious uveitis.

2012

Ocular inflammatory disorders constitute a sight-threatening group of diseases that might be managed according to their severity. Their treatment guidelines experience constant changes with new agents that improve the results obtained with former drugs. Nowadays we can make use of a five step protocol in which topical, periocular and systemic corticosteroids remain as the main therapy for non-infectious uveitis. In addition, immunosuppresive drugs can be added in order to enhance the anti-inflammatory effects and to play the role of corticosteroid-sparing agents. These can be organized in four other steps: cyclosporine and methotrexate in a second one; azathioprine, mycophenolate and tacrol…

medicine.medical_specialtyTreatment protocolCyclophosphamideAdministration TopicalImmunologyAnti-Inflammatory AgentsAzathioprineUveitisInfectious uveitisAdrenal Cortex HormonesmedicineImmunology and AllergyAnimalsHumansIntensive care medicinePharmacologyChlorambucilbusiness.industryTumor Necrosis Factor-alphaGeneral Medicinemedicine.diseaseTacrolimusSurgeryInjections IntravenousPractice Guidelines as TopicMethotrexateImmunotherapybusinessUveitisAlgorithmsImmunosuppressive Agentsmedicine.drugInflammationallergy drug targets
researchProduct

Investigational agents for Crohn's disease.

2010

IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful en…

medicine.medical_specialtybiological therapy. Crohn' s disease. Integrins.Probiotics.Small molecules.DiseaseAdaptive ImmunityReceptors Tumor Necrosis FactorCrohn DiseaseGastrointestinal AgentsmedicineHumansImmunologic FactorsPharmacology (medical)Clinical efficacyIntensive care medicineRandomized Controlled Trials as TopicPharmacologyMitogen-Activated Protein Kinase KinasesBiological therapiesCrohn's diseaseEverolimusEnd pointINVESTIGATIONAL AGENTSbusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineDrugs Investigationalmedicine.diseaseImmunity InnateImmunologyCytokinesRemission rateImmunotherapybusinessCell Adhesion Moleculesmedicine.drugExpert opinion on investigational drugs
researchProduct

Efficacy of subcutaneous and sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a meta-analysis–based comparison

2012

Background: Subcutaneous (SCIT) and sublingual (SLIT) immunotherapy are the 2 most prescribed routes for administering allergen-specific immunotherapy. They were shown to be effective in control of symptoms and in reducing rescue medication use in patients with allergic diseases, but their effectiveness has to be balanced against side effects. In recent years, SLIT has been increasingly prescribed, instead of SCIT, because of improved safety and easy administration. Objective: We assessed which route is the most effective in the treatment of patients with seasonal allergic rhinitis to grass pollen. Methods: An indirect meta-analysis–based comparison between SCIT and SLIT was performed. Trea…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentImmunologySublingual immunotherapy subcutaneous immunotherapy allergic rhinitis grass meta-analysisPlaceboSlitlaw.inventionSettore MED/01 - Statistica MedicaRandomized controlled trialStrictly standardized mean differencelawMeta-analysisInternal medicineImmunologymedicineImmunology and AllergySublingual immunotherapybusinessAdverse effectDesensitization (medicine)
researchProduct